Eric Jonasch, MD

Articles

Dr. Jonasch on the Future of Belzutifan in Clear Cell RCC

August 11th 2022

Eric Jonasch, MD, discusses the future of belzutifan (Welireg) in clear cell renal cell carcinoma.

Dr. Jonasch on the Investigation of Belzutifan in ccRCC

July 8th 2022

Eric Jonasch, MD, discusses the investigation of belzutifan (Welireg) in clear cell renal cell carcinoma.

Advanced Renal Cell Carcinoma: Clinical Practice Pearls

April 4th 2022

Drs Sumeet Bhatia and Eric Jonasch highlight unmet needs in advanced renal cell carcinoma and share clinical pearls.

Role of Community and Academic Centers in the Treatment of Patients with Advanced RCC

March 28th 2022

Dr Sumeet Bhatia highlights the challenges faced by community oncologists who treat patients with advanced renal cell carcinoma and which patients they refer to academic centers.

Toxicities and Quality of Life with IO-IO Therapies in Patients with Advanced RCC

March 28th 2022

Two oncologists describe common adverse events seen with IO-IO combination treatment regimens for advanced renal cell carcinoma, and how they interpret quality of life data from the CheckMate 214 trial.

Advanced Renal Cell Carcinoma and Brain Metastases

March 21st 2022

Experts discuss how to treat advanced renal cell carcinoma with brain metastases and when to refer patients to an academic center.

Nivolumab + Ipilimumab Therapy as Frontline Therapy for Advanced Renal Cell Carcinoma

March 21st 2022

Treating a patient with advanced renal cell carcinoma with ipilimumab-nivolumab based on data from the CheckMate 214 trial.

Patient Profile Presentation: A 41-Year-Old Male with Advanced Renal Cell Carcinoma

March 14th 2022

Sumeet Bhatia, MD, presents the patient profile of a 47-year-old male patient with advanced renal cell carcinoma.

Impact of Adjuvant Pembrolizumab Approval on RCC Treatment Landscape

March 14th 2022

Two key opinion leaders review data from a phase 3 clinical trial assessing the use of lenvatinib plus pembrolizumab for the treatment of advanced renal cell carcinoma.

Adverse Events with IO-TKI Combination Treatment Regimens

March 7th 2022

Two oncologists describe common adverse events seen with I/O–TKI combination treatment regimens for advanced renal cell carcinoma and when they choose to stop the therapy.

Lenvatinib + Pembrolizumab as Frontline Therapy for Advanced Renal Cell Carcinoma

March 7th 2022

Dr Eric Jonasch discusses why he chose to treat his patient’s advanced renal cell carcinoma with lenvatinib-pembrolizumab and how he modifies the dosage throughout treatment.

Considerations for Treatment Decision Making for Advanced Renal Cell Carcinoma

February 28th 2022

Sumeet Bhatia, MD, explains the factors he considers in choosing a treatment for advanced renal cell carcinoma and the role biomarkers have in the process.

Patient Profile Presentation: A 61-Year-Old Man with Advanced Renal Cell Carcinoma

February 28th 2022

Eric Jonasch, MD, presents a real world advanced renal cell carcinoma patient profile and reviews the available first-line IO-TKI combination treatment regimens.

Dr. Jonasch on Pivotal Developments in the Treatment of RCC

October 11th 2021

Eric Jonasch, MD, discusses recent pivotal developments in treating patients with renal cell carcinoma.

Dr. Jonasch on the Role of Inhibiting HIF-2α in Von Hippel-Lindau Disease–Associated RCC

August 20th 2020

Eric Jonasch, MD, discusses the role of inhibiting hypoxia-inducible factor-2α in Von Hippel-Lindau disease–associated renal cell carcinoma.

Dr. Jonasch on Next Steps With MK-6482 in Von Hippel-Lindau Disease–Associated RCC

August 6th 2020

Eric Jonasch, MD, discusses the next steps with the potent, selective, small molecule hypoxia-inducible factor-2α inhibitor MK-6482 in Von Hippel-Lindau disease–associated renal cell carcinoma.

Dr. Jonasch on the Safety Profile of MK-6482 in Von Hippel-Lindau Disease–Associated RCC

July 8th 2020

Eric Jonasch, MD, discusses the safety profile of the investigational oral hypoxia-inducible factor-2α inhibitor MK-6482 in Von Hippel-Lindau disease–associated renal cell carcinoma.

Dr. Jonasch on Modulating the Tumor Microenvironment in RCC

November 12th 2019

Eric Jonasch, MD, discusses how to modulate the tumor microenvironment in renal cell carcinoma.

Dr. Jonasch on Utilizing the Tumor Microenvironment and Epigenetics as Biomarkers in RCC

September 19th 2019

Eric Jonasch, MD, on how understanding features within the tumor microenvironment and mutated epigenetic modifying genes may provide insight on prognosis or treatment strategies in renal cell carcinoma.

Dr. Jonasch on Molecular Understanding of Clear Cell RCC

May 8th 2019

Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the molecular understanding of clear cell renal cell carcinoma (RCC).